Octreotide in Pediatric Patients
2002; Lippincott Williams & Wilkins; Volume: 35; Issue: 5 Linguagem: Inglês
10.1002/j.1536-4801.2002.tb07914.x
ISSN1536-4801
AutoresJanice B. Heikenen, John F. Pohl, Steven L. Werlin, John C. Bucuvalas,
Tópico(s)Pharmaceutical studies and practices
ResumoJournal of Pediatric Gastroenterology and NutritionVolume 35, Issue 5 p. 600-609 Invited Review Octreotide in Pediatric Patients Janice B. Heikenen, Corresponding Author Janice B. Heikenen [email protected] Department of Pediatrics, Marshfield Clinic, Marshfield, WisconsinCorrespondence and reprint requests to Dr. Janice Heikenen, Department of Pediatrics, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, Wisconsin, 54449, U.S.A. (e-mail: [email protected]).Search for more papers by this authorJohn F. Pohl, John F. Pohl Department of Pediatrics, Scott and White Hospital, Texas A &M University Health Science Center, Temple, TexasSearch for more papers by this authorSteven L. Werlin, Steven L. Werlin Department of Pediatrics, The Medical College of Wisconsin, The Children's Hospital of Wisconsin, Milwaukee, WisconsinSearch for more papers by this authorJohn C. Bucuvalas, John C. Bucuvalas Division of Gastroenterology and Nutrition, Children's Hospital Medical Center, Cincinnati, Ohio, U.S.A.Search for more papers by this author Janice B. Heikenen, Corresponding Author Janice B. Heikenen [email protected] Department of Pediatrics, Marshfield Clinic, Marshfield, WisconsinCorrespondence and reprint requests to Dr. Janice Heikenen, Department of Pediatrics, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, Wisconsin, 54449, U.S.A. (e-mail: [email protected]).Search for more papers by this authorJohn F. Pohl, John F. Pohl Department of Pediatrics, Scott and White Hospital, Texas A &M University Health Science Center, Temple, TexasSearch for more papers by this authorSteven L. Werlin, Steven L. Werlin Department of Pediatrics, The Medical College of Wisconsin, The Children's Hospital of Wisconsin, Milwaukee, WisconsinSearch for more papers by this authorJohn C. Bucuvalas, John C. Bucuvalas Division of Gastroenterology and Nutrition, Children's Hospital Medical Center, Cincinnati, Ohio, U.S.A.Search for more papers by this author First published: 01 November 2002 https://doi.org/10.1002/j.1536-4801.2002.tb07914.xCitations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Wynick D, Polak JM, Bloom SR. Somatostatin and its analogues in the therapy of gastrointestinal disease. Pharmacol Ther 1989; 41: 353–70. 10.1016/0163-7258(89)90113-7 CASPubMedWeb of Science®Google Scholar 2Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83: 783–90. 10.1210/endo-83-4-783 CASPubMedWeb of Science®Google Scholar 3Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989; 8: 255–73. CASPubMedWeb of Science®Google Scholar 4Sheppard M, Shapiro B, Pimstone B, et al. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979; 48: 50–3. 10.1210/jcem-48-1-50 CASPubMedWeb of Science®Google Scholar 5Gyr KE, Meier R. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Digestion 1993; 54(suppl 1): 14–9. 10.1159/000201070 CASPubMedWeb of Science®Google Scholar 6Law AW, Gales MA. Octreotide or vasopressin for bleeding esophageal varices. Ann Pharmacother 1997; 31: 237–8. 10.1177/106002809703100216 CASPubMedWeb of Science®Google Scholar 7Tauber MT, Harris AG, Rochiccioli P. Clinical use of the long acting somatostatin analogue octreotide in pediatrics. Eur J Pediatr 1994; 153: 304–10. 10.1007/BF01956407 CASPubMedWeb of Science®Google Scholar 8Meier R, Wettstein AR. Treatment of acute nonvariceal upper gastrointestinal hemorrhage. Digestion 1999; 60(suppl 2): 47–52. 10.1159/000051480 CASPubMedWeb of Science®Google Scholar 9Kohler E, Duberow-Drewe M, Drewe J, et al. Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage. Eur J Clin Pharmacol 1987; 33: 167–71. 10.1007/BF00544562 CASPubMedWeb of Science®Google Scholar 10 Sandostatin LAR® Depot (octreotide acetate for injectable suspension) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2000. Google Scholar 11Ippoliti C. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm 1998; 55: 1573–80. 10.1093/ajhp/55.15.1573 CASPubMedWeb of Science®Google Scholar 12Ferone D, Van Hagen PM, Van Koetsveld PM, et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999; 140: 373–80. 10.1210/endo.140.1.6398 CASPubMedWeb of Science®Google Scholar 13Toro MJ, Birnbaumer L, Redon MC, et al. Mechanism of action of somatostatin. Horm Res 1988; 29: 59–64. 10.1159/000180969 CASPubMedWeb of Science®Google Scholar 14Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495–501. 10.1056/NEJM198312153092406 CASPubMedWeb of Science®Google Scholar 15Moreau JP, DeFeudis FV. Pharmacological studies of somatostatin and somatostatin analogues: therapeutic advances and perspectives. Life Sci 1987; 40: 419–37. 10.1016/0024-3205(87)90107-X CASPubMedWeb of Science®Google Scholar 16Creutzfeldt W, Lembcke B, Folsch UR, et al. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans. Am J Med 1987; 82(5B): 49–54. 10.1016/0002-9343(87)90426-8 CASPubMedWeb of Science®Google Scholar 17Redfern JS, Fortuner 2nd. WJ Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995; 90: 1042–52. CASPubMedWeb of Science®Google Scholar 18Barrons RW. Octreotide in hyperinsulinism. Ann Pharmacother 1997; 31: 239–41. 10.1177/106002809703100217 CASPubMedWeb of Science®Google Scholar 19Glaser B, Hirsch HJ, Landau H. Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr 1993; 123: 644–50. 10.1016/S0022-3476(05)80970-9 CASPubMedWeb of Science®Google Scholar 20 Sandostatin (octreotide acetate). In Physicians' Desk Reference ( 53rd edition). Montvale, NJ: Medical Economics Co; 1999: 2085–6. Google Scholar 21Fried M. Octreotide in the treatment of refractory diarrhea. Digestion 1999; 60(suppl 2): 42–6. 10.1159/000051479 CASPubMedWeb of Science®Google Scholar 22Wales JK. Octreotide treatment associated with adrenal suppression and poor feeding. Arch Dis Child 1994; 70: 553. 10.1136/adc.70.6.553-a CASPubMedWeb of Science®Google Scholar 23DeClue TJ, Malone JI, Bercu BB. Linear growth during long-term treatment with somatostatin analog (SMS 201-995) for persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr 1990; 116: 747–50. 10.1016/S0022-3476(05)82665-4 CASPubMedWeb of Science®Google Scholar 24Odink RJ, Delemarre-van de Waal HA. Growth in a girl with nesidioblastosis during and after treatment with the somatostatin analogue: SMS 201-995. Pediatr Res 1988; 24: 534. 10.1203/00006450-198810000-00122 Web of Science®Google Scholar 25Rodriguez A, del Pozo E, Rodriguez-Arnao MD, et al. Persistence of nocturnal growth hormone (GH) urges may sustain normal infant growth in spite of chronic diurnal suppression with Sandostatin. J Endocrin Invest 1989; 12(suppl 2): 189. Google Scholar 26Roti E, Minelli R, Gardini E, et al. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis. J Endocrinol lnvest 1990; 13: 69–72. 10.1007/BF03348589 CASPubMedWeb of Science®Google Scholar 27Warnet A, Timsit J, Chanson P, et al. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. J Neurosurg 1989; 71: 687–90. 10.3171/jns.1989.71.5.0687 CASPubMedWeb of Science®Google Scholar 28Sahin M, Kartal A, Belviranli M, et al. Effect of octreotide (Sandostatin 201-995) on bile flow and bile components. Dig Dis Sci 1999; 44: 181–5. 10.1023/A:1026630923206 CASPubMedWeb of Science®Google Scholar 29Hussaini SH, Murphy GM, Kennedy C, et al. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastroenterology 1994; 107: 1503–13. 10.1016/0016-5085(94)90556-8 CASPubMedWeb of Science®Google Scholar 30Veysey MJ, Thomas LA, Mallet AI, et al. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut 1999; 44: 675–81. 10.1136/gut.44.5.675 CASPubMedWeb of Science®Google Scholar 31Wasserman E, Hidalgo M, Hornedo J, et al. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy. Bone Marrow Transplant 1997; 20: 711–14. 10.1038/sj.bmt.1700965 CASPubMedWeb of Science®Google Scholar 32Bianco JA, Higano C, Singer J, et al. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 1990; 49: 1194–5. 10.1097/00007890-199006000-00040 CASPubMedWeb of Science®Google Scholar 33Ch'ng JL, Anderson JV, Williams SJ, et al. Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue. Br Med J (Clin Res Ed) 1986; 292: 981–2. 10.1136/bmj.292.6526.981 CASPubMedWeb of Science®Google Scholar 34Dharmsathaphorn K, Sherwin RS, Cataland S, et al. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980; 92: 68–9. 10.7326/0003-4819-92-1-68 CASPubMedWeb of Science®Google Scholar 35Fuessl HS, Zoller WG, Kochen MM, et al. Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995. Klin Wochenschr 1989; 67: 452–5. 10.1007/BF01725142 CASPubMedWeb of Science®Google Scholar 36Sharkey MF, Kadden ML, Stabile BE. Severe posthemicolectomy diarrhea: evaluation and treatment with SMS 201-995. Gastroenterology 1990; 99: 1144–8. 10.1016/0016-5085(90)90637-G CASPubMedWeb of Science®Google Scholar 37Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461–7. 10.1056/NEJM199111213252102 CASPubMedWeb of Science®Google Scholar 38Dean AP, Reed WD. Diarrhoea--an unrecognised hazard of coeliac plexus block. Aust N Z J Med 1991; 21: 47–8. 10.1111/j.1445-5994.1991.tb03001.x CASPubMedGoogle Scholar 39Smelt AH, Meinders AE, Hoekman K, et al. Secretory diarrhea in villous adenoma of rectum: effect of treatment with somatostatin and indomethacin. Prostaglandins 1992; 43: 567–72. 10.1016/0090-6980(92)90116-B CASPubMedWeb of Science®Google Scholar 40Wadler S, Benson 3rd, AB Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998; 16: 3169–78. 10.1200/JCO.1998.16.9.3169 CASPubMedWeb of Science®Google Scholar 41Petrelli NJ, Rodriguez-Bigas M, Rustum Y, et al. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993; 72: 1543–6. 10.1002/1097-0142(19930901)72:5 3.0.CO;2-Z CASPubMedWeb of Science®Google Scholar 42Cascinu S, Fedeli A, Fedeli SL, et al. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology 1994; 51: 70–3. 10.1159/000227313 CASPubMedWeb of Science®Google Scholar 43Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13: 222–6. 10.1200/JCO.1995.13.1.222 CASPubMedWeb of Science®Google Scholar 44Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 148–51. 10.1200/JCO.1993.11.1.148 CASPubMedWeb of Science®Google Scholar 45Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993; 4: 443–5. 10.1097/00001813-199308000-00004 CASPubMedWeb of Science®Google Scholar 46Nikou GC, Polyzos A, Kostalas G, et al. Octreotide administration and gut hormone levels in patients with chemotherapy-induced diarrhea. Hellenic J Gastroenterol 1994; 7: 111–14. Google Scholar 47Geller RB, Gilmore CE, Dix SP, et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Am J Hematol 1995; 50: 167–72. 10.1002/ajh.2830500304 CASPubMedWeb of Science®Google Scholar 48Ippoliti C, Champlin R, Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350–4. 10.1200/JCO.1997.15.11.3350 CASPubMedWeb of Science®Google Scholar 49Ely P, Dunitz J, Rogosheske J, et al. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 1991; 90: 707–10. 10.1016/S0002-9343(05)80059-2 CASPubMedWeb of Science®Google Scholar 50Crouch MA, Restino MS, Cruz JM, et al. Octreotide acetate in refractory bone marrow transplant-associated diarrhea. Ann Pharmacother 1996; 30: 331–6. 10.1177/106002809603000401 CASPubMedWeb of Science®Google Scholar 51Simon DM, Cello JP, Valenzuela J, et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995; 108: 1753–60. 10.1016/0016-5085(95)90137-X CASPubMedWeb of Science®Google Scholar 52Lubeck DP, Bennett CL, Mazonson PD, et al. Quality of life and health service use among HIV-infected patients with chronic diarrhea. J Acquir Immune Defic Syndr 1993; 6: 478–84. 10.1097/00126334-199305000-00008 CASPubMedWeb of Science®Google Scholar 53Nelson JA, Wiley CA, Reynolds-Kohler C, et al. Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet 1988; 1: 259–62. 10.1016/S0140-6736(88)90348-0 CASPubMedWeb of Science®Google Scholar 54Fassler JE, O'Dorisio TM, Goddard CG, et al. Peptides of human immunodeficiency virus (HIV) evoke rat colonic electrolyte secretion inhibitable by the somatostatin analog octreotide. Life Sci 1991; 48:PL 13–7. Google Scholar 55Guenter P, Muurahainen N, Simons G, et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 1993; 6: 1130–8. CASPubMedWeb of Science®Google Scholar 56Guarino A, Berni Canani R, Spagnuolo MI, et al. In vivo and in vitro efficacy of octreotide for treatment of enteric cryptosporidiosis. Dig Dis Sci 1998; 43: 436–41. 10.1023/A:1018839329759 CASPubMedWeb of Science®Google Scholar 57Guarino A, Canani RB, Pozio E, et al. Enterotoxic effect of stool supernatant of Cryptosporidium-infected calves on human jejunum. Gastroenterology 1994; 106: 28–34. 10.1016/S0016-5085(94)94093-2 CASPubMedWeb of Science®Google Scholar 58Smith SS, Shulman DI, O'Dorisio TM, et al. Watery diarrhea, hypokalemia, achlorhydria syndrome in an infant: effect of the long-acting somoatostatin analogue SMS 201-995 on the disease and linear growth. J Pediatr Gastroenterol Nutr 1987; 6: 710–6. 10.1002/j.1536-4801.1987.tb09386.x CASPubMedWeb of Science®Google Scholar 59Lamireau T, Galperine RI, Ohlbaum P, et al. Use of a long acting somatostatin analogue in controlling ileostomy diarrhoea in infants. Acta Paediatr Scand 1990; 79: 871–2. 10.1111/j.1651-2227.1990.tb11572.x CASPubMedWeb of Science®Google Scholar 60Ohlbaum P, Galperine RI, Demarquez JL, et al. Use of a long-acting somatostatin analogue (SMS 201-995) in controlling significant ileal output in a 5-year old child. J Pediatr Gastroenterol Nutr 1987; 6: 466–70. 10.1097/00005176-198705000-00026 CASPubMedWeb of Science®Google Scholar 61Helfer N, Wyss M, Friedli B, et al. Tumeur carcinoide bronchique associee a une secretion exageree de prolactine (PRL) et d'hormone de croissance (STH); traitement par la Sandostatine et la bromocriptine. Schweiz Med Wochenschr 1990; 120(suppl 34): 26. Google Scholar 62Santangelo WC, Strickland AJ, Ducore JM, et al. Long-term treatment of a child with pancreatic cholera syndrome with somatostatin analog (SMS 201-995). Can J Physiol Pharmacol 1986; 64(suppl): 66–7. PubMedGoogle Scholar 63Hunziker UA, Superti-Furga A, Zachmann M, et al. Effects of the long-acting somatostatin analogue SMS 201-995 in an infant with intractable diarrhea. Helv Paediatr Acta 1988; 42: 103–9. Google Scholar 64Jaros W, Biller J, Greer S, et al. Successful treatment of idiopathic secretory diarrhea of infancy with the somatostatin analogue SMS 201-995. Gastroenterology 1988; 94: 189–93. 10.1016/0016-5085(88)90629-4 CASPubMedWeb of Science®Google Scholar 65Couper RT, Berzen A, Berall G, et al. Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillus atrophy. Gut 1989; 30: 1020–4. 10.1136/gut.30.7.1020 CASPubMedWeb of Science®Google Scholar 66Bisset WM, Jenkins H, Booth I, et al. The effect of somatostatin on small intestinal transport in intractable diarrhoea of infancy. J Pediatr Gastroenterol Nutr 1993; 17: 169–75. 10.1002/j.1536-4801.1993.tb10942.x CASPubMedWeb of Science®Google Scholar 67Schmitz J, Ginies JL, Arnaud-Battandier F, et al. Congenital microvillus atrophy, a rare cause of neonatal intractable diarrhoea. Pediatr Res 1982; 16: 1041. Web of Science®Google Scholar 68Pohl JF, Shub MD, Trevelline EE, et al. A cluster of microvillous inclusion disease in the Navajo population. J Pediatr 1999; 134: 103–6. 10.1016/S0022-3476(99)70380-X CASPubMedWeb of Science®Google Scholar 69Kayasseh L, Gyr K, Keller U, et al. Somatostatin and cimetidine in peptic-ulcer haemorrhage. A randomised controlled trial. Lancet 1980; 1: 844–6. 10.1016/S0140-6736(80)91352-5 CASPubMedWeb of Science®Google Scholar 70Coraggio F, Bertini G, Catalano A, et al. Clinical, controlled trial of somatostatin with ranitidine and placebo in the control of peptic hemorrhage of the upper gastrointestinal tract. Digestion 1989; 43: 190–5. 10.1159/000199876 CASPubMedWeb of Science®Google Scholar 71Somerville KW, Henry DA, Davies JG, et al. Somatostatin in the treatment of haematemesis and melaena. Lancet 1985; 1: 130–2. 10.1016/S0140-6736(85)91903-8 CASPubMedWeb of Science®Google Scholar 72Basso N, Bagarani M, Bracci F, et al. Ranitidine and somatostatin. Their effects on bleeding from the upper gastrointestinal tract. Arch Surg 1986; 121: 833–5. 10.1001/archsurg.1986.01400070103021 CASPubMedWeb of Science®Google Scholar 73Christiansen J, Yotis A. The role of somatostatin and a long-acting analogue, SMS 201-995, in acute bleeding due to peptic ulceration. Scand J Gastroenterol Suppl 1986; 119: 109–14. 10.3109/00365528609087438 CASPubMedGoogle Scholar 74Christiansen J, Ottenjann R, Von Arx F. Placebo-controlled trial with the somatostatin analogue SMS 201-995 in peptic ulcer bleeding. Gastroenterology 1989; 97: 568–74. 10.1016/0016-5085(89)90626-4 CASPubMedWeb of Science®Google Scholar 75Lin HJ, Perng CL, Wang K, et al. Octreotide for arrest of peptic ulcer hemorrhage -- a prospective, randomized controlled trial. Hepatogastroenterology 1995; 42: 856–60. CASPubMedWeb of Science®Google Scholar 76Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med 1997; 127: 1062–71. 10.7326/0003-4819-127-12-199712150-00002 CASPubMedWeb of Science®Google Scholar 77Hadengue A. Somatostatin or octreotide in acute variceal bleeding. Digestion 1999; 60(suppl 2): 31–41. 10.1159/000051478 CASPubMedWeb of Science®Google Scholar 78Groszmann RJ. Pharmacological treatment of portal hypertension. Digestion 1996; 57(suppl 1): 103–6. 10.1159/000201411 CASPubMedGoogle Scholar 79Burroughs AK. Somatostatin and octreotide for variceal bleeding. J Hepatol 1991; 13: 1–4. 10.1016/0168-8278(91)90854-5 CASPubMedWeb of Science®Google Scholar 80Avgerinos A, Klonis C, Rekoumis G, et al. A prospective randomized trial comparing somatostatin, balloon tamponade, and the combination of both methods in the management of acute variceal haemorrhage. J Hepatol 1991; 13: 78–83. 10.1016/0168-8278(91)90867-B CASPubMedWeb of Science®Google Scholar 81Huang C, Sheen IS, Chu CM, et al. A prospective randomized controlled trial of sandostatin and vasopressin in the management of acute bleeding esophageal varices. Changgeng Yi Xue Za Zhi 1992; 15: 78–83. CASPubMedGoogle Scholar 82Hwang SJ, Lin HC, Chang CF, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992; 16: 320–5. 10.1016/S0168-8278(05)80663-4 CASPubMedWeb of Science®Google Scholar 83Jenkins SA, Shields R, Davies M, et al. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997; 41: 526–33. 10.1136/gut.41.4.526 CASPubMedWeb of Science®Google Scholar 84Sung JJ, Chung SC, Lai CW, et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993; 342: 637–41. 10.1016/0140-6736(93)91758-E CASPubMedWeb of Science®Google Scholar 85 Kravetz D and Group for the Study of Portal Hypertension. Octreotide vs sclerotherapy in the treatment of acute variceal bleeding. Prospective clinical controlled trial. Preliminary results. Hepatology 1996; 24: 206A. PubMedWeb of Science®Google Scholar 86Poo JL, Bosques F, Garduno R, et al. Octreotide versus emergency sclerotherapy in acute variceal hemorrhage in liver cirrhosis. A randomized, multicenter study. Gastroenterology 1996; 110: 1297A. Web of Science®Google Scholar 87Avgerinos A, Armonis A, Raptis S. Somatostatin and octreotide in the management of acute variceal hemorrhage. Hepatogastroenterology 1995; 42: 145–50. CASPubMedGoogle Scholar 88Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35: 605–15. 10.1053/jhep.2002.31354 Web of Science®Google Scholar 89Gotzsche PC. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev 2002;(1): CD000193. Google Scholar 90Sung JJ, Chung SC, Yung MY, et al. Prospective randomized study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346: 1666–9. 10.1016/S0140-6736(95)92840-5 CASPubMedWeb of Science®Google Scholar 91Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333: 555–60. 10.1056/NEJM199508313330904 CASPubMedWeb of Science®Google Scholar 92D'Amico G, Politi F, Morabito A, et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998; 28: 1206–14. 10.1002/hep.510280507 CASPubMedWeb of Science®Google Scholar 93Jenkins SA, Baxter JN, Critchley M, et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997; 315: 1338–41. 10.1136/bmj.315.7119.1338 CASPubMedWeb of Science®Google Scholar 94Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J Ther 2001; 8: 409–15. 10.1097/00045391-200111000-00005 CASPubMedGoogle Scholar 95Siafakas C, Fox VL, Nurko S. Use of octreotide for the treatment of severe gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr 1998; 26: 356–9. 10.1097/00005176-199803000-00022 CASPubMedWeb of Science®Google Scholar 96Werlin SL. Pancreatitis. In R Wyllie, JS Hyams (ed). Pediatric Gastrointestinal Disease; Pathophysiology, Diagnosis and Management. Philadelphia: WB Saunders Co, 1999; 681–94. Google Scholar 97McKay CJ, Imrie CW, Baxter JN. Somatostatin and somatostatin analogues--are they indicated in the management of acute pancreatitis? Gut 1993; 34: 1622–6. 10.1136/gut.34.11.1622 CASPubMedWeb of Science®Google Scholar 98Jenkins SA, Berein A. Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease. Aliment Pharmacol Ther 1995; 9: 349–61. 10.1111/j.1365-2036.1995.tb00393.x CASPubMedWeb of Science®Google Scholar 99Ladas SD, Raptis SA. Conservative treatment of acute pancreatitis: the use of somatostatin. Hepatogastroenterology 1992; 39: 466–9. CASPubMedGoogle Scholar 100Beechey-Newman N. Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity. Dig Dis Sci 1993; 38: 644–7. 10.1007/BF01316794 CASPubMedWeb of Science®Google Scholar 101Buchler MW, Binder M, Friess H, et al. Potential role of somatostatin and octreotide in the management of acute pancreatitis. Digestion 1994; 55(suppl 1): 16–9. 10.1159/000201183 PubMedWeb of Science®Google Scholar 102Binder M, Uhl W, Friess H, et al. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion 1994; 55(supp 1): 20–3. 10.1159/000201184 PubMedGoogle Scholar 103Andriulli A, Leandro G, Clemente R, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998; 12: 237–45. 10.1046/j.1365-2036.1998.00295.x CASPubMedWeb of Science®Google Scholar 104Uhl W, Buchler MW, Malfertheiner P, et al. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut 1999; 45: 97–104. 10.1136/gut.45.1.97 CASPubMedWeb of Science®Google Scholar 105Uhl W, Anghelacopoulos SE, Friess H, et al. The role of octreotide and somatostatin in acute and chronic pancreatitis. Digestion 1999; 60(suppl 2): 23–31. 10.1159/000051477 CASPubMedWeb of Science®Google Scholar 106Buchler MW, Binder M, Friess H. Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis. Gut 1994; 35(suppl 3): S15–9. 10.1136/gut.35.3_Suppl.S15 CASPubMedWeb of Science®Google Scholar 107Raptis SA, Ladas SD. Therapy of acute pancreatitis with somatostatin. Scand J Gastroenterol Suppl 1994; 207: 34–8. 10.3109/00365529409104192 CASPubMedWeb of Science®Google Scholar 108Bosman-Vermeeren, Veereman-Wauters G, Broos P, et al. Somatostatin in the treatment of a pancreatic pseudocyst in a child. J Pediatr Gastroenterol Nutr 1996; 23: 422–5. 10.1097/00005176-199611000-00011 CASPubMedWeb of Science®Google Scholar 109Dorta G. Role of octreotide and somatostatin in the treatment of intestinal fistulae. Digestion 1999; 60(suppl 2): 53–6. 10.1159/000051481 CASPubMedWeb of Science®Google Scholar 110Present DH. Review article: the efficacy of infliximab in Crohn's disease--healing of fistulae. Aliment Pharmacol Ther 1999; 13(suppl 4): 23–8. 10.1046/j.1365-2036.1999.00026.x CASPubMedWeb of Science®Google Scholar 111Nubiola-Calonge P, Badia JM, Sancho J, et al. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet 1987; 2: 672–4. 10.1016/S0140-6736(87)92452-4 CASPubMedWeb of Science®Google Scholar 112Nubiola P, Badia JM, Martinez-Rodenas F, et al. Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995. Ann Surg 1989; 210: 56–8. 10.1097/00000658-198907000-00009 CASPubMedWeb of Science®Google Scholar 113Munteanu D, Duca S, Vlad L, et al. [Sandostatin treatment in postoperative external fistulae. ] [Article in Romanian]. Chirurgia (Bucur) 1998; 93: 13–21. CASPubMedGoogle Scholar 114Torres AJ, Landa JI, Moreno-Azcoita M, et al. Somatostatin in the management of gastrointestinal fistulas. A muticenter trial. Arch Surg 1992; 127: 97–9; discussion 100. 10.1001/archsurg.1992.01420010115018 CASPubMedWeb of Science®Google Scholar 115Scott NA, Finnegan S, Irving MH. Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study. Acta Gastroenterol Belg 1993; 56: 266–70. CASPubMedWeb of Science®Google Scholar 116Sancho JJ, di Costanzo J, Nubiola P, et al. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula. Br J Surg 1995; 82: 638–41. 10.1002/bjs.1800820521 CASPubMedWeb of Science®Google Scholar 117Hernandez-Aranda JC, Gallo-Chico B, Flores-Ramirez LA, et al. [Treatment of enterocutaneous fistula with or without octreotide and parenteral nutrition.] [Article in Spanish] Nutr Hosp 1996; 11: 226–9. CASPubMedGoogle Scholar 118Julia MV, Parri FJ, Albert A, et al. Treatment of an enteric fistula with somatostatin in a premature. Clin Pediatr 1989; 28: 149–50. 10.1177/000992288902800311 CASPubMedWeb of Science®Google Scholar 119Inamdar S, Slim MS, Bostwick H, et al. Treatment of duodenocutaneous fistula with somatostatin analog in a child with dermatomyositis. J Pediatr Gastroenterol Nutr 1990; 10: 402–4. 10.1002/j.1536-4801.1990.tb10017.x CASPubMedWeb of Science®Google Scholar 120Mozell E, Stenzel P, Woltering EA, et al. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Curr Probl Surg 1990; 6: 301–86. Google Scholar 121Raptis S, Dollinger H, von Berger L, et al. Effects of somatostatin on gastric secretion and gastrin release in man. Digestion 1975; 13: 15–26. 10.1159/000197691 CASPubMedWeb of Science®Google Scholar 122Mozell E, Woltering EA, O'Dorisio TM, et al. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome. Surg Gynecol Obstet 1990; 170: 476–84. CASPubMedWeb of Science®Google Scholar 123Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430–8. 10.1136/gut.38.3.430 CASPubMedWeb of Science®Google Scholar 124Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors. Digestion 1999; 60(suppl 2): 9–14. 10.1159/000051475 CASPubMedWeb of Science®Google Scholar 125Mozell EJ, Cramer AJ, O'Dorisio TM, et al. Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. Arch Surg 1992; 127: 1019–24; discussion 1024-6. 10.1001/archsurg.1992.01420090023004 CASPubMedWeb of Science®Google Scholar 126Arnold R, Wied M, Behr T. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002; 3: 643–56. 10.1517/14656566.3.6.643 CASPubMedGoogle Scholar 127Gray JL, Debas HT, Mulvihill SJ. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg 1991; 126: 1231–5; discussion 1235-6. 10.1001/archsurg.1991.01410340073010 CASPubMedWeb of Science®Google Scholar 128Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 1996; 277: 1359–65. CASPubMedWeb of Science®Google Scholar 129Hasler WL. Dumping syndrome. Curr Treat Options Gastroenterol 2002; 5: 139–45. 10.1007/s11938-002-0061-7 PubMedGoogle Scholar 130Di Lorenzo C, Lucanto C, Flores AF, et al. Effect of octreotide on gastrointestinal motility in children with functional gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 1998; 27: 508–12. 10.1097/00005176-199811000-00002 CASPubMedWeb of Science®Google Scholar 131Di Lorenzo C, Lucanto C, Flores AF, et al. Effect of sequential erythromycin and octreotide on antroduodenal manometry. J Pediatr Gastrorenterol Nutr 1999; 29: 293–6. 10.1097/00005176-199909000-00010 CASPubMedWeb of Science®Google Scholar 132Takahashi A, Tomomasa T, Suzuki N, et al. Small intestinal manometric findings in a patient with total intestinal aganglionosis. J Pediatr Gastroenterol Nutr 2000; 31(suppl 2): S35. Google Scholar 133Nehra V, Camilleri M, Burton D, et al. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol 2001; 96: 1494–8. 10.1111/j.1572-0241.2001.03803.x CASPubMedWeb of Science®Google Scholar 134Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol 1998; 10: 699–702. CASPubMedWeb of Science®Google Scholar 135Rosti L, Bini RM, Chessa M, et al. The effectiveness of octreotide in the treatment of postoperative chylothorax. Eur J Pediatr 2002; 161: 149–50. 10.1007/s00431-001-0891-7 CASPubMedWeb of Science®Google Scholar 136Hanna WT, Maull KI. Sandostatin-induced thrombocytopenia (letter). South Med J 1990; 83: 77. 10.1097/00007611-199001000-00035 CASPubMedWeb of Science®Google Scholar 137Buchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic research. Am J Surg 1992; 163: 125–30; discussion 130-1. 10.1016/0002-9610(92)90264-R CASPubMedWeb of Science®Google Scholar 138Malcolm A, Ellard K. Intestinal perforation associated with octreotide therapy in scleroderma. Am J Gastroenterol 2001; 96: 3206–8. 10.1111/j.1572-0241.2001.05286.x CASPubMedWeb of Science®Google Scholar Citing Literature Volume35, Issue5November 2002Pages 600-609 ReferencesRelatedInformation
Referência(s)